
Annexure A – Author instructions



EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Published under the auspices of the French Société de Chimie Thérapeutique (SCT)

AUTHOR INFORMATION PACK

TABLE OF CONTENTS

• Description	p.1
• Audience	p.1
• Impact Factor	p.1
• Abstracting and Indexing	p.1
• Editorial Board	p.2
• Guide for Authors	p.3



DESCRIPTION

The *European Journal of Medicinal Chemistry* is a **global journal** that publishes studies on all aspects of **medicinal chemistry: organic synthesis; biological behavior; pharmacological activity; drug design; QSAR; molecular modeling; drug-receptor interactions; molecular aspects of drug metabolism; prodrug synthesis and drug targeting**. It provides a medium for publication of original papers, laboratory notes, short or preliminary communications, and invited reviews.

Book Proposals: Elsevier also publishes books in this area. If you have a suggestion for a book topic or would like to submit a book proposal, please contact us at: chemistry@elsevier.com

<http://about.elsevier.com/images/EJMECH2012.gif>

AUDIENCE

Medicinal Chemists, Pharmacologists, Pharmacists, Biochemists and Physicians.

IMPACT FACTOR

2011: 3.346 © Thomson Reuters Journal Citation Reports 2012

ABSTRACTING AND INDEXING

BIOSIS
CNRS/Pascal
Chemical Abstracts
Current Awareness in Biological Sciences
Current Contents/Life Sciences
EMBASE
Elsevier BIOBASE
MEDLINE®
Science Citation Index
Scopus

EDITORIAL BOARD

Editor-in-Chief

H. Galons, INSERM U648, Université Paris Descartes, 4, Avenue de l'observatoire, 75006 Paris, France, Fax: +33 (0)153739875, **Email:** herve.galons@parisdescartes.fr

Associate Editors

S. Guccione, Dipart. di Scienze Farmaceutiche, Università degli Studi di Catania, Viale Andrea Doria 6 - Ed. 12, I-95125 Città Universitaria, Catania, Italy, Fax: +39 95 504572

A. Monge-Vega, Depto. de Química Orgánica y Farmacéutica, Fac. de Farmacia, Universidad de Navarra, Codigo Postal Para Apartados Particulares Y Lista, 31080 Pamplona, Spain, Fax: +34 948 425652

Honorary Editor-in-Chief

O. Lafont, Faculté de Médecine et Pharmacie, Rouen, France

Editorial Advisory Board

J.R. Chretien, Orléans Cedex 2, France

J.C. Dearden, Liverpool, UK

F. Durant, Namur, Belgium

G. Folkers, Switzerland

U. Hacksell, Malmö, Sweden

H.D. Höltje, Düsseldorf, Germany

C. Kunick, Braunschweig, Germany

Y.C. Martin, North Chicago, IL, USA

W.G. Richards, Oxford, England, UK

K. Roy, Kolkata, India

A. Tartar, Vitry en Artois, France

J.P. Tollenaere, Gent, Belgium

V. Tortorella, Bari, Italy

H. van de Waterbeemd, Saint Andre, France

D. Lesuisse, Chilly-Mazarin, France

GUIDE FOR AUTHORS

INTRODUCTION

The *European Journal of Medicinal Chemistry* publishes studies on all aspects of medicinal chemistry, including organic synthesis; biological behaviour; pharmacological activity; drug design; QSAR; molecular modelling; drug-receptor interactions; molecular aspects of drug metabolism; pro-drug synthesis and drug targeting. The journal accepts papers from any country, European or otherwise.

Types of Contributions

The journal provides a medium for publication of the following articles:

Original papers are full papers describing original research of high scientific level and timeliness. They are definitive reports on a full study.

Short communications are shorter pieces of work and report limited studies of the same level as described in original papers.

Preliminary communications are also limited studies but describe particularly novel and significant new findings which shall be developed further in the future.

Laboratory notes are focused on practical aspects. They may deal with an original synthesis of a series of compounds or with new pharmacological methods.

Review articles are specially commissioned by the Editors and may embrace the results of various workers in a given area or may feature recent developments from the author's own laboratory. A review that is distinguished by a novel interpretation or representation of earlier findings is especially suitable. The Editors welcome inquiries concerning the suitability of a particular topic for a review article. In addition, a book review section appears in the journal from time to time.

Contact Details for Submission

The *European Journal of Medicinal Chemistry* uses a web-based online manuscript submission and review system. Authors must submit their manuscript via the online submission page <http://ees.elsevier.com/ejmech>

Page charges

This journal has no page charges.

BEFORE YOU BEGIN

Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/ethicalguidelines>.

Policy and ethics

The work described in your article must have been carried out in accordance with *The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans* <http://www.wma.net/en/30publications/10policies/b3/index.html>; *EU Directive 2010/63/EU for animal experiments* http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; *Uniform Requirements for manuscripts submitted to Biomedical journals* <http://www.icmje.org>. This must be stated at an appropriate point in the article.

Conflict of interest

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication

elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

Contributors

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

Authorship

The text should be arranged in the following order: Introduction, Chemistry, Pharmacology, Results, Discussion, Conclusion and Experimental protocols. Each section should be clearly marked with a separate, numbered heading and may be numbered down to the fourth order.

Analytical data should be included for examination by the editor and referees. However, these data will not be printed if they agree within $\pm 0.4\%$ with calculated values, but may be noted as follows: 'Anal. C₁₄H₁₅NO₃ (C, H, N, O)', with the mentioning under Experimental protocols: 'Analyses indicated by the symbols of the elements or functions were within $\pm 0.4\%$ of the theoretical values'.

Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see <http://www.elsevier.com/copyright>). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

Retained author rights

As an author you (or your employer or institution) retain certain rights; for details you are referred to: <http://www.elsevier.com/authorsrights>.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. Please see <http://www.elsevier.com/funding>.

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

Open access

This journal offers you the option of making your article freely available to all via the ScienceDirect platform. To prevent any conflict of interest, you can only make this choice after receiving notification that your article has been accepted for publication. The fee of \$3,000 excludes taxes and other potential author fees such as color charges. In some cases, institutions and funding bodies have entered into agreement with Elsevier to meet these fees on behalf of their authors. Details of these agreements are available at <http://www.elsevier.com/fundingbodies>. Authors of accepted articles, who wish to take advantage of this option, should complete and submit the order form (available at <http://www.elsevier.com/locate/openaccessform.pdf>). Whatever access option you choose, you retain many rights as an author, including the right to post a revised personal version of your article on your own website. More information can be found here: <http://www.elsevier.com/authorsrights>.

Language and language services

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who require information about language editing and copyediting services pre- and post-submission please visit <http://webshop.elsevier.com/languageservices> or our customer support site at <http://support.elsevier.com> for more information.

Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

Referees

Please submit, with the manuscript, the names, addresses and e-mail addresses of three potential referees. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

PREPARATION

Use of wordprocessing software

It is important that the file be saved in the native format of the wordprocessor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the wordprocessor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your wordprocessor.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Graphical abstract

A Graphical abstract is mandatory for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See <http://www.elsevier.com/graphicalabstracts> for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: [Illustration Service](#).

Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <http://www.elsevier.com/highlights> for examples.

Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Nomenclature

The author is responsible for providing the correct nomenclature which must be consistent and unambiguous. The use of chemical names for drugs is preferred.

Database linking

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

Math formulae

Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article, using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Table footnotes

Indicate each footnote in a table with a superscript lowercase letter.

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Save text in illustrations as 'graphics' or enclose the font.
- Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Produce images near to the desired size of the printed version.
- Submit each figure as a separate file.

A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

Regardless of the application used, when your electronic artwork is finalised, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS: Vector drawings. Embed the font or save the text as 'graphics'.

TIFF: Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is'.

Please do not:

- Supply files that are optimised for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or on the Web only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

Please note: Because of technical complications which can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Text graphics

Text graphics may be embedded in the text at the appropriate position. If you are working with LaTeX and have such features embedded in the text, these can be left. Further, high-resolution graphics files must be provided separately whether or not the graphics are embedded. See further under Electronic artwork.

Tables

Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

Reference style

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result'

List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, *J. Sci. Commun.* 163 (2010) 51–59.

Reference to a book:

[2] W. Strunk Jr., E.B. White, *The Elements of Style*, fourth ed., Longman, New York, 2000.

Reference to a chapter in an edited book:

[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), *Introduction to the Electronic Age*, E-Publishing Inc., New York, 2009, pp. 281–304.

Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier

Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed Instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

Mol files

Mol files (optional): Elsevier would like to enrich your online article by visualizing and providing details of chemical structures you define as the main chemical compounds described. For this purpose, corresponding mol files can be uploaded via the online submission system. Each compound needs to be submitted as a separate mol file. Please use your preferred drawing tool to export chemical structures as mol files and ensure that they are unique, complete and do not contain any R-groups or other variables so that a correct InChI key can be generated. For more information see <http://www.elsevier.com/mol>.

Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone and fax numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
- If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at <http://support.elsevier.com>.

AFTER ACCEPTANCE

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from <http://get.adobe.com/reader>. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: <http://www.adobe.com/products/reader/tech-specs.html>.

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately – please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

Offprints

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

AUTHOR INQUIRIES

For inquiries relating to the submission of articles (including electronic submission) please visit this journal's homepage. For detailed instructions on the preparation of electronic artwork, please visit <http://www.elsevier.com/artworkinstructions>. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at <http://www.elsevier.com/trackarticle>. You can also check our Author FAQs at <http://www.elsevier.com/authorFAQ> and/or contact Customer Support via <http://support.elsevier.com>.

© Copyright 2012 Elsevier | <http://www.elsevier.com>

Information for Authors

Information for Authors

Arzneimittelforschung/Drug Research accepts manuscripts in English covering drug research and development as well as the latest scientific findings on substances and/or products already marketed. The journal accepts manuscripts from the following areas: analytics, bioavailability, biochemistry, bioequivalence, chemistry, clinical pharmacology, drug interactions, efficacy testing, experimental pharmacology, pharmacodynamics, pharmacokinetics, teratology, toxicology as well as questions relating to drug formulation, mathematical and statistical methods for the evaluation of results from industrial investigations as well as clinical trials. Translational medicine aspects are key features of the journal.

When submitted, manuscripts must not have been published elsewhere or be under simultaneous consideration by another journal. The aim of the journal is to disseminate new and reliable experimental data from across the field of drug research to researchers, scientists and doctors worldwide.

N.B.: Incorrect English can result in the immediate rejection of your manuscript whereas correct English will help a speedy publication process. It is in your own interest to ensure that your paper has been read by a native speaker of English; alternatively, you should use a copy-editing service like "American Journal Experts" if you have concerns about the English in your manuscript.

These types of manuscripts will be accepted:

- Original Articles
- Reviews
- Commentaries
- Controversies
- Opinion Papers
- Short Communications
- Letters

Clinical Trials

The Journal supports trial registration. All trials reported must be registered at an official registry recognised by the International Committee of Medical Journal Editors, such as [ClinicalTrials.gov](http://www.clinicaltrials.gov) (www.clinicaltrials.gov) or any of the primary registries on the World Health Organization's International Clinical Trial Registry Platform (www.who.int/ictrp).

Conflict of Interest

Please state the conflicts of interest of all authors. During the online submission process, you will be asked to declare your conflicts of interest. Failure to do so or an incomplete declaration may result in non-publication.

Ethics

The journal is very concerned about ethical standards. Please provide proof that the terms of the latest version of the "World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects" have been adhered to or provide approval of your local ethics committee. The same applies to animals. Please provide proof that experiments involving animals were carried out in compliance with the "Guide for the Care and Use of Laboratory animals" published by the National Academy of Sciences or else provide approval of your local ethics committee.

Manuscript Submission

All manuscripts must be submitted exclusively via online submission at <http://mc.manuscriptcentral.com/amf>

Submissions of hardcopy manuscripts will not be accepted. Please include tables and figures as separate files, they should not be integrated into the main document, but a list with the legends of the figures and tables should be included there. Provide graphic files with sufficient resolution: coloured and black-white bitmaps: 300 dpi; diagrams and line drawings: 600 dpi minimum. Figures

should be serially numbered with Arabic numerals. There should be a clear mark in the manuscript indicating where the figure should be inserted.

Authors are responsible for the correctness of the manuscripts and the list of references. All measurements must be in Systeme International (SI) units.

A. Original Articles

Original papers should deal with investigations and results of high scientific value which have not been published previously.

1. Original papers should not exceed 6 printed pages, i.e. 15 type-written double-spaced manuscript pages of 30 lines of 60 letters each, including references, tables, figures and legends. Please do not use more than one blank space between words and sentences.

2. Preparation of manuscripts

Authors are asked to follow the outline set below:

Page 1: a) title, b) short running title (limit: 40 characters), c) name of the author (no titles or academic grades) and address of the institute(s) where the investigations have been carried out. Should the address of the author at the time of publication differ from the one stated in the paper, the current address should be stated in a footnote, d) complete mailing address of corresponding author including telephone and telefax numbers and e-mail addresses.

Page 2: a) a structured abstract containing no more than 250 words with no abbreviations, b) keywords (3-6 without repeating words in the title).

Page 3 and onwards: a) introduction also indicating the aim of the study, b) materials and methods, c) results: double presentation of data in the form of text, tables or figures should be avoided, d) discussion and conclusions, e) list of references, f) legends of tables and figures. Do include your acknowledgements in the main document.

3. References

a) Text: Citations and references should be numbered consecutively using square brackets in the order in which they are cited in the text, followed by any in tables or legends. Please do not number references under alphabetical order of authors. Do not use footnotes and hyperlinks. If authors are mentioned in the text, only the first author should be given followed by "et al." whenever the reference has three or more authors. Example: "...protein concentrations were determined according to Lowry et al. [1]."

b) List of References: References should be given as plain text. Do not use fields in MS Word, as these are difficult to process later. The references should be listed in numbered order according to the sequence they appear in the text. Preferably, all authors or groups of authors of each publication should be mentioned. The name of the author(s) should be followed by the full title of the paper, name of the journal in which it has been published (abbreviations according to "Index Medicus"), year of publication, volume, first and last page. Abstracts and supplements have to be indicated. Chapters from books have to be cited as follows: author(s), title of chapter, title of book, editor(s), place of publication, publisher, year of publication, first and last page of the chapter. See also the recommendations of the International Committee of Medical Journal Editors (www.icmje.org). Examples:

1 Park HY, Lim H, Pyo H, Kwon YS. Downregulation of matrix metalloproteinase-13 by the root extract of *Caythula officinalis* Kuan and its constituents in IL-1 β -treated chondrocytes. *Planta Med* 2011; 75: 1528-1530

2 Kerner W, Pfeiffer EF. The artificial pancreas. In: Samols E (ed). *The endocrine pancreas*. New York: Raven Press, 1991: 441-456

B. Reviews

Reviews deal with previous research on a certain topic and serve to summarize current findings on the topic so far. The structure of the review will vary from an original paper according to the nature of the review, but please adhere to the guidelines concerning refer-

continued on inside back cover

Continuation from Inside front cover

ences. Please aim at no more than 20 type-written pages and 100 references.

C. Commentaries

They usually follow the article that they discuss, have no special structure and are usually invited. They could also deal with an actual topic such as pivotal new scientific findings in the field. Commentaries should not exceed 6 type-written pages, with a maximum of 20 references. Please adhere to the reference guidelines outlined above.

D. Opinion Papers, Controversies

The structure of these papers will vary from an original paper according to the nature of the topic and argument. Opinion papers present the authors' comprehensive views on current developments in the area and discuss perspectives for the future. Controversies describe a relevant ongoing scientific dispute from an unbiased point of view. They should not exceed 10 type-written pages, with a maximum of 40 references.

Please adhere to the guidelines concerning references outlined above.

E. Short Communications

Short Communications are completed projects of smaller scope and should contain new clinical and experimental data of immediate interest.

1. They should not exceed 2 printed pages (i.e. 6 type-written double-spaced pages in manuscript 30 lines of 60 letters each) and may include 1 table and 1 figure. The list of references at the end of the paper should not exceed 10 citations.

2. The guidelines for the structure of Short Communications are the same as for Original Articles with the following exceptions:
a) no keywords and b) no titles of the papers in the list of references.

F. Letters

This section has been introduced to encourage authors to engage in a free exchange of ideas. The opinions presented do not necessarily reflect the opinions of the Editors.

Page Charges

The publisher will impose a page charge of 160 € per printed page (including 19% VAT) starting with the seventh page.

Reproduction of Color Figures

The journal's fee for color reproduction amounts to € 440 for the first color figure and € 80 for any further figure (including 19% VAT).

Proofs and Reprints as PDF File

Galley proofs will be sent to the corresponding author as a PDF file. At this stage of the production process, only minor corrections (typos, obvious errors in the production process) are accepted. **All other alterations will trigger a de-novo submission.**

The corresponding author receives a PDF file of the published article free of charge.

Copyright

The publisher holds the copyright to all material appearing in the journal. A Copyright Transfer Agreement will be sent to the corresponding author together with the galley proofs. The agreement must be completed and returned to the publishers before the article can be published. **If material taken from foreign sources (including figures, etc.) is included in a manuscript submitted to the Journal it must be indicated as such by citation of the original source and, whenever necessary, permission for reproduction must be obtained from the respective publishing company.**

Editor-in-Chief:

Martin Wehling, MD
Professor of Medicine
Institute of Experimental and
Clinical Pharmacology and Toxicology
Medical Faculty Mannheim
University of Heidelberg
Maybachstr. 14
68169 Mannheim
Germany
E-mail: arzneimittelforschung@thieme.de

Annexure B – Journal publishing agreements

Journal Publishing Agreement

Elsevier Masson SAS

Your article details

Article:	8-Aryl- And Alkyloxycaffeine Analogues As Inhibitors Of Monoamine Oxidase
Corresponding author:	Dr. Jacobus P. Petzer
E-mail address:	jacques.petzer@nwu.ac.za
Journal:	European Journal of Medicinal Chemistry
Our reference	EJMECH4894
PII:	S0223-5234(11)00376-X
DOI:	10.1016/j.ejmech.2011.05.014

Your Status

- I am one author signing on behalf of all co-authors of the manuscript

Data Protection & Privacy

- I do wish to receive news, promotions and special offers about products and services from Elsevier Masson SAS and its affiliated companies worldwide.

Assignment of publishing rights

I hereby assign to Elsevier Masson SAS the copyright in the manuscript identified above (government authors not electing to transfer agree to assign a non-exclusive (ADDED) licence) and any supplemental tables, illustrations or other information submitted therewith that are intended for publication as part of or as a supplement to the manuscript (the "Article") in all forms and media (whether now known or hereafter developed), throughout the world, in all languages, for the full term of copyright, effective when and if the article is accepted for publication. This transfer includes the right to provide the Article in electronic and online forms and systems. No revisions, additional terms or addenda to this Agreement can be accepted without our express written consent. Authors at institutions that place restrictions on copyright assignments, including those that do so due to policies about local institutional

repositories, are encouraged to obtain a waiver from those institutions so that the author can accept our publishing agreement.

Retention of Rights for Scholarly Purposes

I understand that I retain or am hereby granted (without the need to obtain further permission) rights to use certain versions of the Article for certain scholarly purposes, as described and defined below ("Retained Rights"), and that no rights in patents, trademarks or other intellectual property rights are transferred to the journal.

The Retained Rights include the right to use the Preprint or Accepted Author Manuscript for Personal Use, Internal Institutional Use and for ; and the Published Journal Article for Personal Use and Internal Institutional Use.

Author Representations / Ethics and Disclosure

I affirm the Author Representations noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, the Ethics in Publishing policy, and Conflicts of Interest disclosure. For further information see the publishing ethics page at <http://www.elsevier.com/publishingethics> and the journal home page.

Author representations

- The article I have submitted to the journal for review is original, has been written by the stated authors and has not been published elsewhere.
- The article is not currently being considered for publication by any other journal and will not be submitted for such review while under review by this journal.
- The article contains no libellous or other unlawful statements and does not contain any materials that violate any personal or proprietary rights of any other person or entity.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in my article.
- If I am using any personal details or images of patients or research subjects, I have obtained written permission or consent from the patient (or, where applicable, the next of kin). See <http://www.elsevier.com/patientphotographs> for further information.
- If the article was prepared jointly with other authors, I have informed the co-author(s) of the terms of this publishing agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Funding agency and Sponsorship Options

I have also been made aware of the journal's policies with respect to funding agency requirements such as the NIH 'PublicAccess' policy, and the rapid publication 'ArticlesInPress' service. See <http://www.elsevier.com/fundingbodyagreements> for details.

For more information about the definitions relating to this agreement click here.

I have read and agree to the terms of the Journal Publishing Agreement..

12th May 2011

Annexure B



Please print this form and the attached PDF data together with your paper using your printer.



Complete the blanks as requested and send the completed form together with the printout of your paper to the address given below.

Thank you!

Galley Proofs of Thieme Journals

Journal: • **AMF**
Issue / unscheduled: • **unscheduled**
Manuscript No.: • **2012-05-0083**
Corresponding Author • **J.P. Petzer**

Please return permission to print not later than • **3 days**

Notes for the Correction of Galley Proofs

Please make your corrections carefully, since we can only execute one set of corrections and your corrections will be the o.k. for printing.

– **Please do not delete blocks (■) without comment!**

Please answer the questions indicated by the block or add the missing information. If necessary, rephrase sentences as required. Or inform us why from your point of view a specific answer is not relevant or cannot be given.

– Please check illustrations carefully. Mark any necessary corrections on the accompanying laser printouts and

graphic printouts. The original illustrations that are returned to you with these proofs need only and must be sent back to us if corrections are required.

- Please use the standard correction marks. You will find a list of the most important correction marks below.
- Only typesetting errors may be corrected. Subsequent changes differing from the manuscript are very expensive and will be charged to the author. New results may at most be added at the end of the article as addition in proof.
- Do not omit to read the legal information on the other side of this page and remember to order your reprints.

Product Liability Laws: The new product liability laws place a heavy responsibility on you as the author of a scientific publication. This is especially the case when you report on therapeutic modalities and/or drug doses. Thus, please check these details in your galley proofs very carefully. Depending on the degree of the theoretically possible dangers, please ask an experienced colleague or co-worker to also check on these details. During the editorial processing of your manuscript by the publisher this has been proof-read several times and, for example, details of doses carefully checked; however, only you as the author have the necessary specialist knowledge to assess the appropriateness of these details. The responsibility for their correctness lies exclusively with you as the author. Together with our authors we want to reduce the risk of possible injury to patients as well of damage claims and liability proceedings. For this we depend on your cooperation.

Copyright: As stated in the masthead of the journal, with acceptance of your manuscript the publishers acquire for the duration of the legal period of protection the exclusive right for the use of the rights of

exploitation according to copyright laws, especially also the rights of translation, of publication in special issues, the use of individual passages of text for use in schools, the use for electronic text and visual image communication (also on-line, Internet), use in radio or television programmes, production of microcopies, renting or leasing for a fee or payment, duplication by photomechanical or similar means, storage in electronic databases as well as any other virtual storage and retrieval therefrom, in addition to any processing that may be necessary for the exploitation of the above-mentioned rights.

Insofar as the above-mentioned rights are managed by an exploitation company the publisher is entitled to enter into the necessary contracts with the relevant exploitation companies; the publisher is also empowered to enter into contracts with third parties for the exploitation of these rights.

Please forward any questions or offers addressed to you concerning any one of the above-mentioned utilisation rights to the publisher for processing.

Permission to Print

☞ Please fill in

The enclosed proof is ready for printing after the corrections made by me have been incorporated. I have read and understood the sections on product liability laws and copyright.

Place/Date

Signature

How can we best reach you in case there are any questions?

Phone

E-mail



Please send the corrected galley proof and this accompanying leaflet to the following address:

Georg Thieme Verlag
Journal Production
• **Katrin Grohe**
• **AMF/ 2012-05-0083**
Postfach 30 11 20
70451 Stuttgart

Fax:
• **+49 711 8931 392**

